WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Roche

RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

www.roche.com.

Roche RSS Channel

Filters
List of articles in category Roche
Title Published Date
Roche obtains license for EGFR lung cancer assays and will develop Tarceva companion diagnostic test 23 November 2010
Roche announces implementation plans for its Operational Excellence Program 17 November 2010
Roche reports promising Phase II results with new targeted approach in advanced melanoma 09 November 2010
FDA approves Herceptin for HER2-positive metastatic stomach cancer 25 October 2010
Roche Group posts solid sales growth in first nine months 20 October 2010
Roche recognised as global healthcare leader in Dow Jones Sustainability Index 13 September 2010
Roche announces Operational Excellence initiative 08 September 2010
Roche acquires BioImagene, a leading provider of digital pathology laboratory solutions 23 August 2010
Roche posts good half year results 23 July 2010
Testing for Human Papillomavirus Genotypes 16 and 18 Detects Cervical Pre-Cancer Missed by Pap Test 09 July 2010
RoACTEMRA: New hope for children with systemic Juvenile Idiopathic Arthritis 21 June 2010
Phase III study showed Avastin-based regimen helped women with advanced ovarian cancer 07 June 2010
EDUCARE (EDUcation for Cancer in African REgions) Project 10 May 2010
Roche Group sustained its strong sales growth in the first three months of 2010 28 April 2010
Roche acquires Medingo Ltd. and expands its position in the growing insulin delivery systems market 15 April 2010
Roche uniquely positioned to deliver long-term growth 22 March 2010
Roche and Biogen Idec decide to suspend Ocrelizumab treatment 11 March 2010
Phase III study of Avastin in advanced stomach cancer did not meet primary endpoint 26 February 2010
US FDA approves Rituxan/MabThera for the most common type of adult leukemia 23 February 2010
Roche study drug may offer valuable new treatment option for patients with type 2 diabetes 12 February 2010
  • Start
  • Prev
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • Next
  • End

Business & Industry

  • Pfizer to acquire Global Blood Therapeutics for $5.4 billion to enhance presence in rare hematology
  • Roche's subcutaneous formulation of Tecentriq demonstrates positive Phase III results
  • Bayer Consumer Health leaders propose new principles for science-led self-care
  • GSK signs agreement to support pandemic preparedness in Europe
  • Pfizer and BioNTech advance COVID-19 vaccine strategy with study start of next-generation vaccine candidate based on enhanced spike protein design

Research & Development

  • New method of nasal vaccine delivery could lead to better vaccines for HIV and COVID-19
  • Research identifies, exploits vulnerability in certain high-risk cancers
  • Scientists create long-acting injectable drug delivery system for tuberculosis
  • Treating cancer by sticking cells in place
  • Vitamin K prevents cell death: a new function for a long-known molecule
  • Disparities in United States COVID-19 vaccine distribution
  • New needle-free nasal vaccine shows promise for COVID-19

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. Roche
  4. Roche's subcutaneous formulation of Tecentriq demonstrates positive Phase III results

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.